AKT1 and colorectal carcinoma: Although current research findings have shown that EVO has an anticancer effect on CRC by activating the PI3K/AKT signaling pathway, there is still insufficient detailed research data to clearly demonstrate the molecular mechanism or targets of EVO in CRC treatment.